Abstract
Although peptide drugs make up only about 2% of all drugs approved by the United States Food and Drug Administration (FDA), they play important roles in the treatment of certain diseases where no small molecule drugs or therapeutic antibodies can fulfil. A primary reason for the strong preference of small molecules over peptides is the latter’s susceptibility to degradation by human proteases, resulting in very short systemic half-lives. To circumvent this, peptide chemists have resorted to introducing unnatural amino acids and chemical modifications to enhance their metabolic stabilities. Hence, understanding how peptide drugs are metabolized by the human body will help in the design of more stable peptide drugs. This review covers 25 FDA-approved peptide drugs up to 20 residues in length and details their metabolic and degradation pathways in the human body after administration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
All data and materials can be found in the reference section.
References
Agersø H, Seiding Larsen L, Riis A, Lövgren U, Karlsson MO, Senderovitz T (2004) Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol 58(4):352–358. https://doi.org/10.1111/j.1365-2125.2004.02175.x
Al-Merani SAMA, Brooks DP, Chapman BJ, Munday KA (1978) The half-lives of angiotensin II, angiotensin II-amide, angiotensin III and renin in the circulatory system of the rat. J Physiol 278:471–490. https://doi.org/10.1113/jphysiol.1978.sp012318
Allen NE, Hobbs JN, Alborn WE (1987) Inhibition of peptidoglycan biosynthesis in Gram-positive bacteria by LY146032. Antimicrob Agents Chemother 31(7):1093–1099. https://doi.org/10.1128/aac.31.7.1093
Alton KB, Kosoglou T, Baker S, Affrime MB, Cayen MN, Patrick JE (1998) Disposition of 14 C-eptifibatide after intravenous administration to healthy men. Clin Ther 20(2):307–323. https://doi.org/10.1016/s0149-2918(98)80094-5
Andersson K-E, Longstreth J, Brucker BM, Campeau L, Cheng L, Francis L, Fein S (2019) Pharmacokinetic and pharmacodynamic properties of a micro-dose nasal spray formulation of desmopressin (AV002) in healthy water-loaded subjects. Pharm Res 36:92. https://doi.org/10.1007/s11095-019-262
Angiomax package insert (2016) https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020873s036lbl.pdf. Accessed 7 Dec 2020
Bellibas SE, Gao R, Lehoux D, Mehta S, Rizkalla B, Narang M, Prats J, Villiger J, Ge J (2014) Pharmacokinetics and pharmacodynamics of Bivalirudin (Angiomax®) in Chinese patients undergoing PCI. J Am Coll Cardiol 64(16 Supplement):C144–C145
Benvenuto M, Benziger DP, Yankelev S, Vigliani G (2006) Pharmacokinetics and tolerability of daptomycin at dosesup to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 50(10):3245–3249. https://doi.org/10.1128/AAC.00247-06
Block GA, Chertow GM, Sullivan JT, Deng H, Mather O, Tomlin H, Serenko M (2019) An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism. PLoS One 14(3):e0213774. https://doi.org/10.1371/journal.pone.0213774
Boccon-Gibod L, Iversen P, Persson BE (2009) Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer. Expert Rev Anticancer Ther 9(12):1737–1743. https://doi.org/10.1586/era.09.150
Borel JF, Feurer C, Gubler HU, Stähelin H (1976) Biological effect of cyclosporin A: a new anti-lymphocytic agent. Agents Actions 6(4):468–475. https://doi.org/10.1007/BF01973261
Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W (2007) Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 119(6):1497–1503. https://doi.org/10.1016/j.jaci.2007.02.012
Buck ML (2015) Bivalirudin as an alternative to heparin for anticoagulation in infants and children. J Pediatr Pharmacol Ther 20(6):408–417. https://doi.org/10.5863/1551-6776-20.6.408
Brogden RN, Faulds D (1995) Goserelin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer. Drugs Aging 6(4):324–343. https://doi.org/10.2165/00002512-199506040-00007
Bronstein M, Musolino N, Jallad R, Cendrost JM, Ramis J, Obach R, Leselbaum A, Catus F (2005) Pharmacokinetic profile of lanreotide Autogel® in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol 63:514–519. https://doi.org/10.1111/j.1365-2265.2005.02372.x
Bruno BJ, Miller GD, Lim CS (2013) Basics and recent advances in peptide and protein drug delivery. Ther Deliv 4(11):1443–1467. https://doi.org/10.4155/tde.13.104
Busby RW, Kessler MM, Bartolini WP, Bryant AP, Hannig G, Higgins CS, Solinga RM, Tobin JV, Wakefield JD, Kurtz CB et al (2013) Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther 344(1):196–206. https://doi.org/10.1124/jpet.112.199430
Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L et al (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumours. N Engl J Med 371(3):224–233. https://doi.org/10.1056/NEJMoa1316158
Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, Pico AM, Valimaki M, Zgliczynski W (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide autogel) in the management of acromegaly. J Clin Endocrinol Metab 87(1):99–104. https://doi.org/10.1210/jcem.87.1.8153
Castinetti F, Saveanu A, Morange I, Brue T (2009) Lanreotide for the treatment of acromegaly. Adv Ther 26(6):600–612. https://doi.org/10.1007/s12325-009-0035-4
Cendros JM, Peraire C, Trocóniz IF, Obach R (2005) Pharmacokinetics and population pharmacodynamic analysis of lanreotide autogel. Metabolism 54(10):1276–1281. https://doi.org/10.1016/j.metabol.2005.04.014
Cetrotide package insert (2000) https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21197lbl.pdf. Accessed 7 Dec 2020
Chan RL, Chaplin MD (1985) Identification of major urinary metabolites of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone in the rhesus monkey. Drug Metab Dispos 13(5):566–571
Chen X, Shen G, Jianj J, Liu H, Hu K, Darstein C, Lasher J, Hu P (2014) Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study. Clin Ther 36(8):1196–1210. https://doi.org/10.1016/j.clinthera.2014.06.006
Cheer SM, Plosker GL, Simpson D, Wagstaff AJ (2005) Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women. Drugs 65(18):2639–2655. https://doi.org/10.2165/00003495-200565180-00011
Chrisp P, Goa KL (1990) Nafarelin A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions. Drugs 39(4):523–551. https://doi.org/10.2165/00003495-199039040-00005
Chrisp P, Goa KL (1991) Goserelin A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions. Drugs 41(2):254–288. https://doi.org/10.2165/00003495-199141020-00008
Christians U, Strohmeyer S, Kownatzki R, Schiebel HM, Bleck J, Greipel J, Kohlhaw K, Schottmann R, Sewing KF (1991) Investigations on the metabolic pathways of cyclosporine: I. Excretion of cyclosporine and its metabolites in human bile–isolation of 12 new cyclosporine metabolites. Xenobiotica 21(9):1185–1198. https://doi.org/10.3109/00498259109039559
Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H et al (2010) Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363(6):532–541. https://doi.org/10.1056/NEJMoa0906393
Cockshott ID (2000) Clinical pharmacokinetics of goserelin. Clin Pharmacokinet 39(1):27–48. https://doi.org/10.2165/00003088-200039010-00003
Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM et al (2012) A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med 366(10):914–924. https://doi.org/10.1056/NEJMoa1105743
Cubicin package insert (2011) https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021572s038lbl.pdf. Accessed 7 Dec 2020
Deeks ED (2010) Histrelin in advanced prostate cancer. Drugs 70(5):623–630. https://doi.org/10.2165/11204800-000000000-00000
Di L (2015) Strategic approaches to optimizing peptide ADME properties. AAPS J 17(1):134–143. https://doi.org/10.1208/s12248-014-9687-3
Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD (2003) Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 47(4):1318–1323. https://doi.org/10.1128/aac.47.4.1318-1323.2003
Erak M, Bellmann-Sickert K, Els-Heindl S, Beck-Sickinger AG (2018) Peptide chemistry toolbox—transforming natural peptides into peptide therapeutics. Bioorg Med Chem 26:2759–2765. https://doi.org/10.1016/j.bmc.2018.01.012
Falck P, Guldseth H, Asberg A, Midtvedt K, Reubsaet JL (2007) Determination of ciclosporin A and its six main metabolites in isolated T-lymphocytes and whole blood using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 852(1–2):345–352. https://doi.org/10.1016/j.jchromb.2007.01.039
Feelders RA, Yasothan U, Kirkpatrick P (2012) Pasireotide. Nat Rev Drug Discov 11(8):597–598. https://doi.org/10.1038/nrd3788
Firazyr package insert (2011) https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022150s000lbl.pdf. Accessed 7 Dec 2020
Firmagon package insert (2015) https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022201s009lbl.pdf. Accessed 7 Dec 2020
Fjellestad-Paulsen A, Lundin S (1996) Metabolism of vasopressin, oxytocin and their analogues [Mpa1, d-Arg8]-vasopressin (dDAVP) and [Mpa1, d-Tyr(Et)2, Thr4, Orn8]-oxytocin (antocin) in human kidney and liver homogenates. Regul Pept 67(1):27–32. https://doi.org/10.1016/s0167-0115(96)00103-6
Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, Rinehart J, Rosenwaks Z, Scott RT Jr, Schoolcraft W et al (2001) Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 75(1):38–45. https://doi.org/10.1016/s0015-0282(00)01638-1
Fosgerau K, Hoffmann T (2015) Peptide therapeutics: current status and future directions. Drug Discov Today 20(1):122–128. https://doi.org/10.1016/j.drudis.2014.10.003
Freeman DJ (1991) Pharmacology and pharmacokinetics of cyclosporine. Clin Biochem 24(1):9–14. https://doi.org/10.1016/0009-9120(91)90084-r
Friss GJ, Bundgaard H (1992) Kinetics of degradation of cyclosporin A in acidic aqueous solution and its implication in its oral absorption. Int J Pharm 82(1–2):79–83. https://doi.org/10.1016/0378-5173(92)90075-D
Ganirelix package insert (1999) https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21057lbl.pdf. Accessed 7 Dec 2020
Giapreza package insert (2017) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209360s000lbl.pdf. Accessed 7 Dec 2020
Gladwell TD (2002) Bivalirudin: a direct thrombin inhibitor. Clin Ther 24(1):38–58. https://doi.org/10.1016/s0149-2918(02)85004-4
Gomez-Panzani E, Chang S, Ramis J, Landolfi MM, Bakker B (2012) Sustained biochemical control in patients with acromegaly treated with lanreotide depot 120 mg administered every 4 weeks, or an extended dosing interval of 6 or 8 weeks: a pharmacokinetic approach. Res Rep Endocr Disord 2:79–84. https://doi.org/10.2147/RRED.S38149
Gras J (2009) Icatibant for hereditary angioedema. Drugs Today (Barc) 45(12):855–864. https://doi.org/10.1358/dot.2009.45.12.1424267
Greinacher A, Warkentin TE (2008) The direct thrombin inhibitor hirudin. Thromb Haemost 99(5):819–829. https://doi.org/10.1160/TH07-11-0693
Harris AG (1994) Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut 35(3 Suppl):S1–S4. https://doi.org/10.1136/gut.35.3_suppl.s1
Hashemzadeh M, Furukawa M, Goldsberry S, Movahed MR (2008) Chemical structures and mode of action of intravenous glycoprotein IIb/IIIa receptor blockers: a review. Exp Clin Cardiol 13(4):192–197
Henninot A, Collins JC, Nuss JM (2018) The current state of peptide drug discovery: back to the future? J Med Chem 61(4):1382–1414. https://doi.org/10.1021/acs.jmedchem.7b00318
Hide M, Fukunaga A, Maehara J, Eto K, Hao J, Vardi M, Nomoto Y (2020) Efficacy, pharmacokinetics, and safety of icatibant for the treatment of Japanese patients with an acute attack of hereditary angioedema: a phase 3 open-label study. Allergol Int 69:268–273. https://doi.org/10.1016/j.alit.2019.08.012
Hirsch HJ, Gillis D, Strich D, Chertin B, Farkas A, Lindenberg T, Gelber H, Spitz IM (2005) The histrelin implant: a novel treatment for central precocious puberty. Pediatrics 116(6):e798–e802. https://doi.org/10.1542/peds.2005-0538
Hoitink MA, Beijnen JH, Boschma MUS, Bult A, Hop E, Nijholt J, Versluis C, Wiese G, Underberg WJM (1997) Identification of the degradation products of gonadorelin and three analogues in aqueous solution. Anal Chem 69(24):,4972–4978. https://doi.org/10.1021/ac970634x
Integrilin package insert (2011) https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020718s034lbl.pdf. Accessed 7 Dec 2020
Jegorov A, Havlíček V, Sedmera P (1996) An unusual side chain C-C cleavage at the MeBmt amino acid in cyclosporin A. Amino Acids 10(2):145–151. https://doi.org/10.1007/BF00806587
Kamuda JA, Mazzola N (2018) Plecanatide (Trulance) for chronic idiopathic constipation and irritable bowel syndrome with constipation. Pharm Ther 43(4):207–232
Katsila T, Siskos AP, Tamvakopoulos C (2012) Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry. Mass Spectrom Rev 31(1):110–133. https://doi.org/10.1002/mas.20340
Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA (2019) Bremelanotide for the treatment of hypoactive sexual desire disorder. Obstet Gynecol 134(5):899–908. https://doi.org/10.1097/AOG.0000000000003500
Köhler M, Harris A (1988) Pharmacokinetics and haematological effects of desmopressin. Eur J Clin Pharmacol 35(3):281–285. https://doi.org/10.1007/BF00558266
Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C et al (2015) Afamelanotide for erythropoietic protoporphyria. N Engl J Med 373(1):48–59. https://doi.org/10.1007/s40257-016-0184-6
Lau JL, Dunn MK (2018) Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem 26(1):2700–2707. https://doi.org/10.1016/j.bmc.2017.06.052
Leach JK, Spencer K, Mascelli M, McCauley TG (2015) Pharmacokinetics of single and repeat doses of icatibant. Clin Pharmacol Drug Dev 4(2):105–111. https://doi.org/10.1002/cpdd.138
Lin TH, Hu K, Flarakos J, Sharr-McMahon M, Mangold JB, He H, Wang Y (2013) Assessment of the absorption, metabolism and excretion of [14 C] pasireotide in healthy volunteers using accelerator mass spectrometry. Cancer Chemother Pharmacol 72(1):181–188. https://doi.org/10.1007/s00280-013-2183-0
Linzess package insert (2017) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202811s013lbl.pdf. Accessed 7 Dec 2020
Lohr JW, Willsky GR, Acara MA (1998) Renal drug metabolism. Pharm Rev 50(1):107–141
Love BL, Johnson A, Smith LS (2014) Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome. Am J Health Syst Pharm 71(13):1081–1091. https://doi.org/10.2146/ajhp130575
Lupron package insert (2014) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020517s036_019732s041lbl.pdf. Accessed 7 Dec 2020
Magni F, Arcelloni C, Paroni R, Fermo I, Bonini PA, Del Puppo M, Manzocchi A, Galli Kienle M (1994) Open-chain peptides obtained by acidic hydrolytic cleavage of cyclosporin A. Biol Mass Spectrom 23(8):514–518. https://doi.org/10.1002/bms.1200230809
Mahato RI, Narang AS, Thoma L, Miller DD (2003) Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 20(2–3):153–214. https://doi.org/10.1615/critrevtherdrugcarriersyst.v20.i23.30
Martin-Gago P, Aragón E, Gomez-Caminals M, Fernández-Carneado J, Ramón R, Martin-Malpartida P, Verdaguer X, López-Ruiz P, Colás B, Cortes MA et al (2013) Insights into structure-activity relationships of somatostatin analogs. Molecules 18(12):14564–14584. https://doi.org/10.3390/molecules181214564
Matsuda S, Koyasu S (2000) Mechanisms of action of cyclosporine. Immunopharmacology 47(2–3):119–125. https://doi.org/10.1016/s0162-3109(00)00192-2
Maurer G, Loosli HR, Schreier E, Keller B (1984) Disposition of cyclosporine in several animal species and man. I. Structural elucidation of its metabolites. Drug Metab Dispos 12(1):120–126
McKeage K (2013) Pasireotide: a review of its use in Cushing’s disease. Drugs 73(6):563–574. https://doi.org/10.1007/s40265-013-0052-0
Merseburger AS, Hupe MC (2016) An update on Triptorelin: current thinking on androgen deprivation therapy for prostate cancer. Adv Ther 33(7):1072–1093. https://doi.org/10.1007/s12325-016-0351-4
Minder EI, Barman-Aksoezen J, Schneider-Yin X (2017) Pharmacokinetics and pharmacodynamics of afamelanotide and its clinical use. Clin Pharmacokinet 56(8):815–823. https://doi.org/10.1007/s40262-016-0501-5
Minirin oral tablets package insert (2003) https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21333slr001_Minirin_oral.pdf. Accessed 7 Dec 2020
Muller FO, Terblanchè J, Schall R, van Zyl Smit R, Tucker T, Marais K, Groenewoud G, Porchet HC, Weiner M, Hawarden D (1997) Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. Br J Clin Pharmacol 44(4):335–341. https://doi.org/10.1046/j.1365-2125.1997.t01-1-00592.x
Neoral package insert (2009) https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050715s027,050716s028lbl.pdf. Accessed 7 Dec 2020
Oberyé JJ, Mannaerts BM, Kleijn HJ, Timmer CJ (1999) Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part 1. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. Fertil Steril 72(6):1001–1005. https://doi.org/10.1016/s0015-0282(99)00413-6
Ogami C, Tsuji Y, Kasai H, Hiraki Y, Yamamoto Y, Matsunaga K, Karube Y, To H (2017) Evaluation of pharmacokinetics and the stability of daptomycin in serum at various temperatures. Int J Infect Dis 57:38–43. https://doi.org/10.1016/j.ijid.2017.01.017
Oleson FB, Berman CL, Li AP (2004) An evaluation of the P450 inhibition and induction potential of daptomycin in primary human heapatocytes. Chem Biol Interact 150(2):137–147. https://doi.org/10.1016/j.cbi.2004.08.004
Out HJ, Mannaerts BM (2002) The gonadotrophin-releasing hormone antagonist ganirelix—history and introductory data. Hum Fertil (Camb) 5(1):5–10. https://doi.org/10.1080/1464727992000199771
Parsabiv package insert (2017) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208325Orig1s000Lbledt.pdf. Accessed 7 Dec 2020
Pasala T, Sattayaprasert P, Bhat PK, Athappan G, Gandhi S (2014) Clinical and economic studies of eptifibatide in coronary stenting. Ther Clin Risk Manag 10:603–614. https://doi.org/10.2147/TCRM.S35664
Pauletti GM, Gangwar S, Siahaan TJ, Aubé J, Borchardt RT (1997) Improvement of oral peptide bioavailability: peptidomimetics and prodrug strategies. Adv Drug Deliv Rev 27:235–256. https://doi.org/10.1016/s0169-409x(97)00045-8
Periti P, Mazzei T, Mini E (2002) Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet 41(7):485–504. https://doi.org/10.2165/00003088-200241070-00003
Perry CM, Brogden RN (1996) Goserelin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders. Drugs 51(2):319–346. https://doi.org/10.2165/00003495-199651020-00009
Pitocin package insert (2014) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018261s031lbl.pdf. Accessed 7 Dec 2020
Qvit N, Rubin SJS, Urban TJ, Mochly-Rosen D, Gross ER (2017) Peptidomimetic therapeutics: scientific approaches and opportunities. Drug Discov Today 22(2):454–462. https://doi.org/10.1016/j.drudis.2016.11.003
Rao SSC (2018) Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation. Therap Adv Gastroenterol 11:1–14. https://doi.org/10.1177/1756284818777945
Rembratt A, Graugaard-Jensen C, Senderovitz T, Norgaard JP, Djurhuus JC (2004) Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55–70 years. Eur J Clin Pharmacol 60(6):397–402. https://doi.org/10.1007/s00228-004-0781-9
Rittig S, Jensen AR, Jensen KT, Pedersen EB (1998) Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects. Clin Endocrinol 48:235–241
Robinson AG (1976) DDAVP in the treatment of central diabetes insipidus. N Engl J Med 294(10):507–511. https://doi.org/10.1056/NEJM197603042941001
Rothstein RD, Friedenberg FK (2013) Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation. Expert Opin Pharmacother 14(15):2125–2132. https://doi.org/10.1517/14656566.2013.833605
Sandostatin package insert (2003) https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19667scm044_Sandostatin_lbl.pdf. Accessed 7 Dec 2020
Saltzstein D, Shore ND, Moul JW, Chu F, Concepcion R, de la Motte S, McLane JA, Atkinson S, Yang A, Crawford ED (2018) Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects. Ther Adv Urol 10(2):43–50. https://doi.org/10.1177/1756287217738150
Sawyer WH, Acosta M, Manning M (1974) Structural changes in the arginine vasopressin molecule that prolong its antidiuretic action. Endocrinology 95(1):140–149. https://doi.org/10.1210/endo-95-1-140
Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips DR, Nannizzi L, Arfsten A, Campbell AM, Charo IF (1993) Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 268(2):1066–1073
Scenesse package insert (2019) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf. Accessed 7 Dec 2020
Schlegel P (2009) A review of the pharmacokinetic and pharmacological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer. BJU Int 103 Suppl 2:7–13. https://doi.org/10.1111/j.1464-410X.2009.08383.x
Seitchik J, Castillo M (1982) Oxytocin augmentation of dysfunctional labor. I. Clinical data. Am J Obstet Gynecol 144(8):899–905. https://doi.org/10.1016/0002-9378(82)90181-8
Shah I, Khan SO, Malhotra S, Fischell T (2009) Eptifibatide: the evidence for its role in the management of acute coronary syndromes. Core Evid 4:49–65. https://doi.org/10.2147/ce.s6008
Sheppard M, Shapiro B, Pimstone B, Kronheim S, Berelowitz M, Gregory M (1979) Metabolic clearance and plasma half disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab 48(1):50–53. https://doi.org/10.1210/jcem-48-1-50
Signifor package insert (2014) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203255s000lbl.pdf. Accessed 7 Dec 2020
Simpson J, Zhang Q, Ozaeta P, Aboleneen H (1998) A specific method for the measurement of cyclosporin A in human whole blood by liquid chromatography-tandem mass spectrometry. Ther Drug Monit 20(3):294–300. https://doi.org/10.1097/00007691-199806000-00009
Sjöholm I (1969) Oxytocinase and its possible significance in the degradation of oxytocin during pregnancy. FEBS Lett 4(3):135–139. https://doi.org/10.1016/0014-5793(69)80215-2
Sofianos ZD, Katsila T, Kostomitsopoulos N, Balafas V, Matsoukas J, Tselios T, Tamvakopoulos C (2008) In vivo evaluation and in vitro metabolism of leuprolide in mice—mass spectrometry based biomarker measurement for efficacy and toxicity. J Mass Spectrom 43(10):1381–1392. https://doi.org/10.1002/jms.1416
Somatuline package insert (2014) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022074s011lbl.pdf. Accessed 7 Dec 2020
Sonesson A, Rasmussen BB (2013) In vitro and in vivo human metabolism of degarelix, a gonadotropin-releasing hormone receptor blocker. Drug Metab Dispos 41(7):1339–1346. https://doi.org/10.1124/dmd.113.051706
Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F et al (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355(21):2203–2216. https://doi.org/10.1056/NEJMoa062437
Synarel package insert (2012) https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019886s030lbl.pdf. Accessed 7 Dec 2020
Tally FP, Zeckel M, Wasilewski MM, Carini C, Berman CL, Drusano GL, Oleson FB Jr (1999) Daptomycin: a novel agent for gram-positive infections. Expert Opin Investig Drugs 8(1):1223–1238. https://doi.org/10.1517/13543784.8.8.1223
Thomas RH, Allmond K (2013) Linaclotide (Linzess) for irritable bowel syndrome with constipation and for chronic idiopathic constipation. Pharm Ther 38(3):154–160
Tiberg F, Roberts J, Cervin C, Johnsson M, Sarp S, Tripathi AP, Linden M (2015) Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers. Brit J Clin Pharm 80(3):460–472. https://doi.org/10.1111/bcp.12698
Todd DJ (1994) Erythropoietic protoporphyria. Br J Dermatol 131(6):751–766. https://doi.org/10.1111/j.1365-2133.1994.tb08577.x
Trelstar package insert (2011) https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020715s024,021288s021,022437s002lbl.pdf. Accessed 7 Dec 2020
Trulance package insert (2017) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208745lbl.pdf. Accessed 7 Dec 2020
Ueno H, Matsuo K (1991) High-performance liquid chromatography followed by radioimmunoassay for the determination of a luteinizing hormone-releasing hormone analogue, leuprorelin, and its metabolite. J Chromatogr 566:57–66. https://doi.org/10.1016/0378-4347(91)80110-x
van Kats JP, de Lannoy LM, Danser AHJ, van Meegen JR, Verdouw PD, Schalekamp MADH (1997) Angiotensin II type 1 (AT1) receptor–mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo. Hypertension 30:42–49. https://doi.org/10.1161/01.hyp.30.1.42
van Mourik IDM, Thomson M, Kelly DA (1999) Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients. Liver Transpl Surg 5(2):107–111
Vantas package insert (2014) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021732s015lbl.pdf. Accessed 7 Dec 2020
Vasostrict package insert (2014) https://ww.accessdata.fda.gov/drugsatfda_docs/label/2014/204485Orig1s000lbl.pdf. Accessed 7 Dec 2020
Veale JJ, McCarthy HM, Palmer G, Dyke CM (2005) Use of bivalirudin as an anticoagulant during cardiopulmonary bypass. J Extra Corpor Technol 37(3):296–302
Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M (2010) Synthetic therapeutic peptides: science and market. Drug Discov Today 15(1–2):40–56. https://doi.org/10.1016/j.drudis.2009.10.009
Vyleesi package insert (2019) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf. Accessed 7 Dec 2020
Vyleesi review (2019) https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf. Accessed 7 Dec 2020
Wacher VJ, Silverman JA, Zhang Y, Benet LZ (1998) Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 87(11):1322–1330. https://doi.org/10.1021/js980082d
Wang J, Yadav V, Smart AL, Tajiri S, Basit AW (2015) Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs. Mol Pharm 12(3):966–973. https://doi.org/10.1021/mp500809f
Williams MR, Walker KJ, Turkes A, Blamey RW, Nicholson RI (1986) The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 53(5):629–636. https://doi.org/10.1038/bjc.1986.106
Woodworth JR, Nyhart EH Jr., Brier GL, Wolny JD, Black HR (1992) Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 36(2):318–325. https://doi.org/10.1128/aac.36.2.318
Wu B, Melhem M, Subramanian R, Chen P, Sloey BJ, Fouqueray B, Hock MB, Skiles GL, Chow AT, Lee E (2018) Clinical pharmacokinetics and pharmacodynamics of Etelcalcetide, a novel calcimimetic for treatment of secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis. J Clin Pharmacol 58(6):717–726. https://doi.org/10.1002/jcph.1090
Zoladex package insert (2015) https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019726s059,020578s037lbl.pdf. Accessed 7 Dec 2020
Acknowledgements
I thank the Agency for Science, Technology and Research (A*STAR) Biomedical Research Council (BMRC) for financial support.
Funding
Funding for this review was obtained from the Agency for Science, Technology and Research Biomedical Research Council, Singapore.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author of this review declare no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Brian Chia, C.S. A Review on the Metabolism of 25 Peptide Drugs. Int J Pept Res Ther 27, 1397–1418 (2021). https://doi.org/10.1007/s10989-021-10177-0
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10989-021-10177-0